ArticleNPJ Parkinson's disease2025
Neuroimaging transcriptomic analyses of Parkinson's disease highlight molecular, cellular, and neurobiological mechanisms.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Parkinson's disease is a debilitating disorder with a profound symptomatic burden. While genomic studies of PD have made advances in recent years, there remains a gap in our understanding of the relationship between PD genes and the neurologic changes involved in disease progression. In this work, we aim to characterize the mechanisms by which germline susceptibility variants affect gene expression and the downstream effects on neurobiology. We perform a transcriptome-wide association study of PD (N = 482,730) and identify 74 transcript-level associations with the disease. These findings derive from gene expression models trained in bulk tissue samples from 13 different brain regions, and 6 tissues with clinical relevance to the brain, including whole blood. We explore the resulting associations using eQTL colocalization, the chromatin-state discovery approach CoRE-BED, and our NeuroimaGene atlas of neuroimaging transcriptomics. In this work, we implicate enhancer disruption for STX1B and HIP1R in neurons and oligodendrocytes respectively in PD pathophysiology and show that reduced expression of PD risk genes broadly is predictive of cortical thinning and dysregulation of somatomotor circuitry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.